Physician profile
Christopher C Peterson
NPI 1164535282
$872.22
in general payments reported to CMS, 2019-2025
13 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $34.41 · 2021: $122 · 2022: $46.99 · 2023: $14.20 · 2024: $136 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $245.19 | 2024-2025 | Gemtesa |
| Novo Nordisk INC | $183.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $95.08 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $69.80 | 2024-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $59.46 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Allergan, INC. | $54.87 | 2019-2020 | |
| Glaxosmithkline, LLC. | $36.26 | 2021-2025 | Trelegy Ellipta |
| Amgen INC. | $28.26 | 2019-2020 | |
| Pfizer INC. | $26.39 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $24.90 | 2022 | |
| Astellas Pharma US INC | $19.61 | 2025 | Veozah |
| Exact Sciences Corporation | $14.91 | 2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $14.20 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.